Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir

被引:135
作者
Nolan, D
Upton, R
McKinnon, E
John, M
James, I
Adler, B
Roff, C
Vasikaran, S
Mallal, S [1 ]
机构
[1] Royal Perth Hosp, Dept Clin Immunol, Ctr Clin Immunol & Biomed Stat, Perth, WA 6000, Australia
[2] Murdoch Univ, Murdoch, WA 6150, Australia
[3] Royal Perth Hosp, Dept Nucl Med, Perth, WA, Australia
[4] Royal Perth Hosp, Dept Core Clin Pathol & Biochem, Perth, WA, Australia
关键词
bone mineral density; HAART; indinavir; lipodystrophy syndrome; nelfinavir; protease inhibitors; osteopenia; osteoporosis; subcutaneous fat wasting;
D O I
10.1097/00002030-200107060-00009
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background and objectives: To determine the factors contributing to changes in bone mineral density (BMD) over time in HIV-infected patients receiving highly active antiretroviral therapy (HAART). Methods: Analyses of lumbar spine BMD in 183 male Caucasian participants in the Western Australian HIV Cohort study, comprising a longitudinal analysis of data from 54 patients on stable HAART regimens, and a cross-sectional analysis comparing data from 131 protease inhibitor (PI)-treated patients and 52 PI-naive (including 28 antiretroviral treatment-naive) patients. Results: Average lumbar spine BMD remained stable or increased over the time frame considered. Although there was no evidence of a change of average BMD over time in patients receiving nelfinavir (P = 0.92), there was evidence of increasing bone density in the indinavir group (average increase, 0.31 z-score per year; P < 0.001). Lower initial z-scores in the longitudinal analysis were significantly associated with lower pre-HAART BMI (P = 0.003), consistent with results of the cross-sectional analysis in which lowest BMI prior to initial dual X-ray absorptiometry scan was associated with decreased BMD (P = 0.02, overall group). Although PI therapy was also associated with decreased BMD in a univariate analysis of the cross-sectional data (P = 0.04), this effect was abrogated in a multiple linear regression analysis (P = 0.11) with lowest BMI remaining significant (P = 0.04). Conclusions: We found no evidence, overall, of accelerated bone loss in patients treated with nelfinavir- or indinavir-containing HAART regimens, and propose that indinavir therapy may be associated with an increase in bone mineral density over time. Pre-HAART BMI was an independent and powerful determinant of an individual's initial z-score in the longitudinal analysis, and adjustment for this effect in a cross-sectional analysis abrogated the association between P1 therapy and decreased lumbar spine z-score. (C) 2001 Lippincott Williams & Wilkins.
引用
收藏
页码:1275 / 1280
页数:6
相关论文
共 20 条
[1]   Associations of fat and muscle masses with bone mineral in elderly men and women [J].
Baumgartner, RN ;
Stauber, PM ;
Koehler, KM ;
Romero, L ;
Garry, PJ .
AMERICAN JOURNAL OF CLINICAL NUTRITION, 1996, 63 (03) :365-372
[2]   MESENCHYMAL STEM-CELLS IN IN BONE-DEVELOPMENT, BONE REPAIR, AND SKELETAL REGENERATION THERAPY [J].
BRUDER, SP ;
FINK, DJ ;
CAPLAN, AI .
JOURNAL OF CELLULAR BIOCHEMISTRY, 1994, 56 (03) :283-294
[3]   High fatty acid content in rabbit serum is responsible for the differentiation of osteoblasts into adipocyte-like cells [J].
Diascro, DD ;
Vogel, RL ;
Johnson, TE ;
Witherup, KM ;
Pitzenberger, SM ;
Rutledge, SJ ;
Prescott, DJ ;
Rodan, GA ;
Schmidt, A .
JOURNAL OF BONE AND MINERAL RESEARCH, 1998, 13 (01) :96-106
[4]   Body composition of a young, multiethnic, male population [J].
Ellis, KJ .
AMERICAN JOURNAL OF CLINICAL NUTRITION, 1997, 66 (06) :1323-1331
[5]   Obesity, and bone strength and ''mass'': A tutorial based on insights from a new paradigm [J].
Frost, HM .
BONE, 1997, 21 (03) :211-214
[6]  
HAGUENAUER D, 2000, COCHRANE DATABASE SY, V4
[7]  
HOY J, 2000, 7 C RETR OPP INF SAN
[8]  
Kotler DP, 2000, ANN NY ACAD SCI, V904, P546, DOI 10.1111/j.1749-6632.2000.tb06514.x
[9]   BONE-MINERAL DENSITY MEASURED BY DUAL-ENERGY X-RAY ABSORPTIOMETRY IN NORMAL MEN [J].
KROGER, H ;
LAITINEN, K .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 1992, 22 (07) :454-460
[10]   Stimulation of vitamin A1 acid signaling by the HIV protease inhibitor indinavir [J].
Lenhard, JM ;
Weiel, JE ;
Paulik, MA ;
Furfine, ES .
BIOCHEMICAL PHARMACOLOGY, 2000, 59 (09) :1063-1068